Toronto Dominion Bank Acquires 1,028 Shares of Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank raised its holdings in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 7.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 15,104 shares of the medical instruments supplier’s stock after acquiring an additional 1,028 shares during the period. Toronto Dominion Bank’s holdings in Insulet were worth $3,291,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Trexquant Investment LP bought a new stake in shares of Insulet during the 2nd quarter valued at $756,000. Sit Investment Associates Inc. raised its position in shares of Insulet by 16.0% during the 2nd quarter. Sit Investment Associates Inc. now owns 15,945 shares of the medical instruments supplier’s stock valued at $3,475,000 after acquiring an additional 2,200 shares during the last quarter. Synovus Financial Corp grew its holdings in shares of Insulet by 2.7% in the 2nd quarter. Synovus Financial Corp now owns 3,816 shares of the medical instruments supplier’s stock valued at $836,000 after buying an additional 100 shares during the period. Eagle Asset Management Inc. grew its holdings in shares of Insulet by 2.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 240,770 shares of the medical instruments supplier’s stock valued at $52,473,000 after buying an additional 5,319 shares during the period. Finally, WINTON GROUP Ltd grew its holdings in shares of Insulet by 2.5% in the 2nd quarter. WINTON GROUP Ltd now owns 6,555 shares of the medical instruments supplier’s stock valued at $1,429,000 after buying an additional 157 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PODD. Canaccord Genuity Group boosted their price target on shares of Insulet from $250.00 to $290.00 and gave the company a “buy” rating in a report on Friday, August 5th. Robert W. Baird boosted their price target on shares of Insulet from $300.00 to $315.00 and gave the company an “outperform” rating in a report on Friday, November 4th. Piper Sandler raised shares of Insulet from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $235.00 to $340.00 in a report on Friday, November 4th. Jefferies Financial Group began coverage on shares of Insulet in a research note on Wednesday, October 12th. They issued a “hold” rating and a $260.00 target price for the company. Finally, StockNews.com raised shares of Insulet from a “sell” rating to a “hold” rating in a research note on Wednesday, November 9th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $300.62.

Insulet Trading Up 1.0 %

Insulet stock opened at $292.63 on Friday. The firm has a 50-day moving average of $256.69 and a 200-day moving average of $242.22. Insulet Co. has a one year low of $181.00 and a one year high of $320.00. The company has a debt-to-equity ratio of 3.22, a current ratio of 3.98 and a quick ratio of 3.00. The company has a market cap of $20.32 billion, a price-to-earnings ratio of 1,219.29 and a beta of 0.79.

Insider Transactions at Insulet

In other news, SVP Michael P. Spears sold 13,658 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $308.99, for a total value of $4,220,185.42. Following the sale, the senior vice president now directly owns 8,792 shares of the company’s stock, valued at approximately $2,716,640.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Dan Manea sold 200 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the sale, the senior vice president now directly owns 3,158 shares of the company’s stock, valued at approximately $930,409.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael P. Spears sold 13,658 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $308.99, for a total transaction of $4,220,185.42. Following the completion of the sale, the senior vice president now directly owns 8,792 shares in the company, valued at $2,716,640.08. The disclosure for this sale can be found here. Insiders sold a total of 28,858 shares of company stock worth $7,756,109 in the last three months. Insiders own 0.90% of the company’s stock.

Insulet Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.